-
公开(公告)号：US08586045B2
公开(公告)日：2013-11-19
申请号：US13179846
申请日：2011-07-11
申请人： Joerg Zeller , Kristian T. Poulsen , Yasmina Noubia Abdiche , Jaume Pons , Sierra Lee Jones Collier , Arnon Rosenthal
发明人： Joerg Zeller , Kristian T. Poulsen , Yasmina Noubia Abdiche , Jaume Pons , Sierra Lee Jones Collier , Arnon Rosenthal
IPC分类号： A61K39/395 , C12P21/08 , C07K16/00
CPC分类号： C07K16/18 , A61K31/4045 , A61K39/3955 , A61K2039/505 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/70 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
摘要翻译： 本发明的特征在于通过施用抗CGRP拮抗剂抗体来预防或治疗CGRP相关疾病如血管舒缩症状，包括头痛（例如偏头痛，丛集性头痛和紧张性头痛）和热潮红的方法。 还描述了拮抗剂抗体G1和衍生自指向CGRP的G1的抗体。
-
2.发明授权Antagonist antibodies directed against calcitonin gene-related peptide and methods using same 有权针对降钙素基因相关肽的拮抗剂抗体及使用其的方法公开(公告)号：US08007794B2
公开(公告)日：2011-08-30
申请号：US12093638
申请日：2006-11-02
申请人： Joerg Zeller , Kristian T. Poulsen , Yasmina Noubia Abdiche , Jaume Pons , Sierra Leigh Jones Collier , Arnon Rosenthal
发明人： Joerg Zeller , Kristian T. Poulsen , Yasmina Noubia Abdiche , Jaume Pons , Sierra Leigh Jones Collier , Arnon Rosenthal
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K16/18 , A61K31/4045 , A61K39/3955 , A61K2039/505 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/70 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
摘要翻译： 本发明的特征在于通过施用抗CGRP拮抗剂抗体来预防或治疗CGRP相关疾病如血管舒缩症状，包括头痛（例如偏头痛，丛集性头痛和紧张性头痛）和热潮红的方法。 还描述了拮抗剂抗体G1和衍生自指向CGRP的G1的抗体。
-
3.发明申请ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME 有权针对CALCITONIN基因相关肽的ANTAGONIST抗体及其使用方法公开(公告)号：US20090220489A1
公开(公告)日：2009-09-03
申请号：US12093638
申请日：2006-11-02
申请人： Joerg Zeller , Kristian T. Poulsen , Yasmina Noubia Abdiche , Jaume Pons , Sierra Leigh Jones Collier , Arnon Rosenthal
发明人： Joerg Zeller , Kristian T. Poulsen , Yasmina Noubia Abdiche , Jaume Pons , Sierra Leigh Jones Collier , Arnon Rosenthal
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K16/18 , A61K31/4045 , A61K39/3955 , A61K2039/505 , C07K16/26 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/34 , C07K2317/52 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/70 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
摘要： The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
摘要翻译： 本发明的特征在于通过施用抗CGRP拮抗剂抗体来预防或治疗CGRP相关疾病如血管舒缩症状，包括头痛（例如偏头痛，丛集性头痛和紧张性头痛）和热潮红的方法。 还描述了拮抗剂抗体G1和衍生自指向CGRP的G1的抗体。
-
4.发明授权Method for reducing a level of LDL-cholesterol by an antibody that specifically binds to PCSK9 有权通过特异性结合PCSK9的抗体降低LDL-胆固醇水平的方法公开(公告)号：US08426363B2
公开(公告)日：2013-04-23
申请号：US13225265
申请日：2011-09-02
申请人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
发明人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
摘要翻译： 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。
-
公开(公告)号：US08080243B2
公开(公告)日：2011-12-20
申请号：US12558312
申请日：2009-09-11
申请人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
发明人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
摘要翻译： 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。
-
公开(公告)号：US20120014951A1
公开(公告)日：2012-01-19
申请号：US13225265
申请日：2011-09-02
申请人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
发明人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
IPC分类号： A61K39/395 , A61P3/00 , A61P9/10 , A61P3/06 , A61P9/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
-
7.发明授权Isolated nucleic acid encoding an antibody which specifically binds to PCSK9 and a host cell that produces the antibody 有权编码与PCSK9特异性结合的抗体的分离的核酸和产生抗体的宿主细胞公开(公告)号：US08399646B2
公开(公告)日：2013-03-19
申请号：US13225119
申请日：2011-09-02
申请人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
发明人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
摘要翻译： 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。
-
公开(公告)号：US20120015435A1
公开(公告)日：2012-01-19
申请号：US13225119
申请日：2011-09-02
申请人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
发明人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Yuli Wang
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
摘要翻译： 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。
-
公开(公告)号：US20100068199A1
公开(公告)日：2010-03-18
申请号：US12558312
申请日：2009-09-11
申请人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Xiayang Qiu , Pavel Strop , Yuli Wang
发明人： Hong Liang , Yasmina Noubia Abdiche , Javier Fernando Chaparro Riggers , Bruce Charles Gomes , Julie Jia Li Hawkins , Jaume Pons , Xiayang Qiu , Pavel Strop , Yuli Wang
IPC分类号： A61K39/395 , C07K16/00 , C12N5/10 , C07H21/04 , A61P9/00
CPC分类号： C07K16/40 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2299/00 , C07K2317/24 , C07K2317/33 , C07K2317/76 , C07K2317/92
摘要： The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
摘要翻译： 本发明提供了与抗蛋白转化酶枯草杆菌蛋白酶Kexin 9型（PCSK9）结合的拮抗抗体，其抗原结合部分和适体。 还提供了针对肽的抗体，其中抗体结合PCSK9。 本发明还提供了获得这样的抗体和抗体编码核酸的方法。 本发明还涉及使用这些抗体及其抗原结合部分来降低LDL-胆固醇水平和/或用于治疗和/或预防心血管疾病（包括治疗高胆固醇血症）的治疗方法。
-
公开(公告)号：US20230250158A1
公开(公告)日：2023-08-10
申请号：US18173772
申请日：2023-02-23
CPC分类号： C07K16/10 , A61P31/14 , A61K2039/505
摘要： The present application relates to neutralizing antibodies or antigen-binding fragments thereof against betacoronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), to nucleic acid(s) encoding such neutralizing antibodies or antigen-binding fragments thereof, and to mixture and compositions comprising such antibodies, antigen-binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are able to block betacoronavirus entry into cells and/or to induce complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) against betacoronavirus-infected cells. Methods and uses of the antibodies, antigen-binding fragments thereof, nucleic acid(s) or compositions, including therapeutic, diagnostic, and preventative methods and uses for betacoronavirus infections and related diseases such as COVID-19, are also described.
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.039 秒)
